Thomas A. Baillie, PhD

Dr. Baillie is Dean of the School of Pharmacy at the University of Washington.  He was most recently Global Vice President of Drug Metabolism & Pharmacokinetics at Merck until 2008.  Prior to this, Dr. Baillie served on the faculties of University of London, Univ. of California San Francisco, and University of Washington.  Dr. Baillie is respected internationally as an authority on the application of mass spectrometry to studies on drug metabolism, with emphasis on the generation of chemically-reactive products of biotransformation.  He was awarded a Fogarty Senior International Fellowship from the NIH (1988), was the recipient of the James R. Gillette Award from the American Society for Pharmacology & Experimental Therapeutics (2001), and received the Lifetime Achievement Award from the International Isotope Society (2009). In 2010, he was elected as a Fellow of the Royal Society of Chemistry.

Simon Campbell, CBE FRS PhD

Dr. Campbell has more than 30 years of experience in the pharmaceutical industry, most recently as Senior Vice President for Worldwide Discovery and Medicinals R&D Europe at Pfizer. He has co-authored over 110 publications and patents, and was a key member of the research teams that discovered Cardura, Norvasc, and Viagra. His scientific contributions have been recognized by the Royal Society of Chemistry Award for Medicinal Chemistry (1989), the Herschberg Award from the American Chemical Society (1997), and the Industry Research Institute (US) Achievement Award (1997). Dr. Campbell is a Past President of the Royal Society of Chemistry, was elected Fellow of the Royal Society in 1999, was appointed CBE by the Queen in 2006 for Services to Science, and in 2007 was awarded the prestigious Galen Medal in Therapeutics.

Barry Furr, OBE FMedSci PhD

Former Chief Scientist and Head of the Project Evaluation Group at AstraZeneca, Professor Furr has vast experience in the area of anticancer drug discovery as well as many years spent in the areas of cardiovascular and musculoskeletal inflammation research. He is a past Chairman of the Society for Endocrinology, Fellow of both the Academy of Medical Sciences and Institute of Biology, and is a trustee of Cancer Research UK and the Breast Cancer Campaign. His research and leadership has led to multiple pharmaceutical treatments, for a variety of cancers, which are currently benefiting patients around the globe. This work has also been recognized by numerous awards, including The Society for Drug Research Award for the discovery and development of Zoladex, The Jubilee Medal of the Society for Endocrinology for cancer research and services to Endocrinology, and the Officer of Order of the British Empire (OBE) for services to cancer drug discovery.

[ back to top ]

[ back to home ]